TD Private Client Wealth’s LENZ Therapeutics LENZ Stock Holding History

TD Private Client Wealth’s Portfolio LENZ Stock Details LENZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$626	Buy	+163	New	+$812	﹤0.01%	1618

Other funds holding LENZ

Squarepoint New York $90.8B AUM 26.98% 1-Year Est. Return

C WorldWide Group Copenhagen, Denmark $3.96B AUM 10.41% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $188M AUM 88.51% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

KBC Group Brussels, Belgium $47.9B AUM 37.61% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

State of Alaska Department of Revenue Juneau, Alaska $9.6B AUM 34.67% 1-Year Est. Return

TD Private Client Wealth's LENZ Position: Q3 2026 in Review

TD Private Client Wealth opened a new position in LENZ Therapeutics (LENZ) in Q3 2026: 163 shares worth $626. The stake represents ﹤0.01% of the portfolio and ranks #1618 among its holdings.

45 funds tracked by Wall St. Rank hold LENZ as of Q3 2026.

TD Private Client Wealth held 163 shares of LENZ Therapeutics worth $626 as of Q3 2026.
LENZ Therapeutics was a new TD Private Client Wealth position in Q3 2026.
LENZ Therapeutics made up ﹤0.01% of TD Private Client Wealth's portfolio in Q3 2026, its #1618 holding.
45 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q3 2026.

Based on TD Private Client Wealth's 13F filing for Q3 2026, filed 28 Oct 2026.